SOTIO Biotech is developing potent immunotherapies for patients with cancer, focusing on advancing safer and more effective treatments through clinical development.

SOTIO Biotech

SOTIO Biotech | 8,879 followers on LinkedIn. Shaping the future of cancer immunotherapies by translating compelling science into patient benefit. | SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a next-generation PD-1-inhibiting cytokine, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.

Isabelle Serve

Jens Hennecke

Head of Business Development and Licensing | Pharmaceuticals, Life Sciences

Norbert Prenzel

Roman Kovář

We will present at the American Association for Cancer Research conference on Tumor-body interactions: The Roles of Micro- and Macroenvironment in Cancer in Boston, MA. Šárka Vošahlíková ’s poster will focus on the role of PARP inhibitors for successful immunotherapy in #ovariancancer . #Biotechnology #CancerResearch #jsmePPF

This week, we will attend the Connective Tissue Oncology Society 2024 annual meeting in San Diego. Our Chief Executive Officer, Radek Spisek , Ph.D., and Senior Medical Director, Vivi Boura, MD, PhD , will connect with fellow sarcoma experts and discuss our ongoing efforts in advancing treatments for #sarcoma , such as through our DUET-01 clinical trial studying BOXR1030. #Biotechnology #CancerResearch #jsmePPF

Klára Plačková , junior scientist, is presenting at the INTERNATIONAL PAPILLOMAVIRUS SOCIETY - IPVS Conference in Edinburgh, UK, sharing insights on how tissue structure influences the pattern and density of immune cells that infiltrate tumors in HPV-related cancers. #Biotechnology #CancerResearch #IPVC2024 #jsmePPF

We are presenting a preclinical update on SOT201, a next-generation PD-1-targeting immunocytokine, this week at #SITC24 . New data support SOT201’s ability to reinvigorate exhausted immune cells in PD-1 sensitive and resistant tumor models. SOTIO’s two other posters at Society for Immunotherapy of Cancer (SITC) Annual Meeting provide an overview of the ongoing Ph1 clinical trial of SOT201 (VICTORIA-01) and explore the use of a chimeric PGC-1α transgene to enhance CAR T cell activity. Read more in our press release: https://bit.ly/3As1deT #Biotechnology #cancer #CancerResearch #SITC2024 #jsmePPF

#DidYouKnow that #PancreaticCancer is one of the deadliest cancers, with a 5-year survival rate of just 12%? Our Phase 1/2 CLAUDIO-01 trial is currently evaluating SOT102, a Claudin 18.2 ADC, for the treatment of pancreatic cancer. At SOTIO, we’re committed to changing the landscape of #cancer treatment by advancing innovative therapies that aim to improve the lives of patients battling devastating illnesses like pancreatic cancer. Learn more about SOT102 candidate at: https://bit.ly/48CzAfS #PancreaticCancerAwareness #PCAM #Biotechnology #CancerResearch #jsmePPF

Lung cancer is the most common #cancer in men and the second most common in women. As we observe #LungCancerAwarenessMonth , we reaffirm our dedication to advancing therapies for patients facing this significant unmet medical need. #Biotechnology #CancerResearch #jsmePPF

Next month we will be at the World ADC Event Series conference in San Diego. Martin Steegmaier , Chief Scientific Officer, will present on some of the latest progress in our portfolio of #ADC candidates for solid tumors. If you’re attending, be sure to stop by his presentation, or reach out to connect. #WorldADC #Biotechnology #CancerResearch #jsmePPF

Today we had the pleasure of welcoming the new Swiss ambassador, H.E. Urs Bucher, and his embassy colleagues to SOTIO Biotech ’s Prague office. Radek Spisek , Pavel Solsky and I gave our guests a tour of our lab space and presented the latest on SOTIO’s efforts to advance #cancer #research . Together with Luděk Sojka Sojka from our affiliate company SCTbio , we also visited lab space that is focused on the manufacturing of #celltherapies . SOTIO is one of the leaders in creating and promoting Czech-Swiss relations. Thank you for your visit and engaging in interesting discussion, Your Excellency! #cancerresearch #Switzerland #jsmePPF

Richard Kapsa

SOTIO will present three posters at the Society for Immunotherapy of Cancer (SITC) Meeting next month in Houston, Texas, including data supporting SOT201, a next-generation PD-1 targeting immunocytokine. Learn more details in our press release: https://bit.ly/48eWZU8 #SITC2024 #Biotechnology #DrugDevelopment #CancerResearch #jsmePPF

Our CEO, Radek Spisek , recently joined the Labiotech.eu #BeyondBiotechpodcast to discuss the pioneering developments in bispecific antibody-drug conjugates (ADCs) and their potential to revolutionize the field of #oncology . On bispecific ADCs, Radek shares: “There are good scientific reasons to believe that there are clinical situations or tumors that make sense to target [two antigens] at the same time, rather than to just go after one.” Tune in to learn more about SOTIO’s ADC platform, including SOT102, now in Phase 1/2 clinical studies in the U.S. and Europe: https://bit.ly/4eLwp7I #ADC #biotechnology #jsmePPF

SOTIO Biotech develops immunotherapies for cancer treatment, focusing on advancing safer and effective options through clinical development. The company self-describes as focusing on a broad pipeline addressing various solid tumor types.

SOTI

COM:SOTIO

SOTIO Biotech

Filings Not Available